Price chart (1D to 10Y)
Licensed market data — shown to members, not published to the open web.
Valuation vs Instaport thresholds (P/E, PEG, P/FCF, P/S)
Licensed market data — shown to members, not published to the open web.
Profile
From SEC filingsCompany description
Purpose and Mission Founded in 1992, Anika Therapeutics, Inc. (“Anika” or “Company”) is a global leader in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The Company leverages proprietary hyaluronic acid (“HA”) technology to develop highly differentiated products. Driven by strong partnerships with physicians, Anika is dedicated to pioneering HA-based innovations that redefine orthopedic care. Our mission is to restore active living, empower surgeon choice, and enhance patient outcomes worldwide. Anika ’ s Mission: “Together, we restore active living and redefine what’s possible with hyaluronic acid.” Anika ’ s Core Values: ● Trust and Respect: We build trust and show respect in every interaction. ● Quality: We are committed to quality as we work to improve people’s lives. ● Empowerment & Teamwork: We are empowered as a team to make decisions that drive impact. ● Focus: We focus on what matters most and are driven to be better every day. Strategy In October 2024, we announced a strategic shift to concentrate on our OA Pain Management and Regenerative Solutions portfolios. This strategic decision involved the sale of Arthrosurface Incorporated on October 31, 2024 and the sale of Parcus Medical, LLC on March 7, 2025, both of which were acquired in early 2020 under a previous management strategy. As we look ahead, our focused strategy, driven by HA-based products, positions us to offer truly innovative treatments in areas of unmet need and substantial, growing markets.
Read the full filing description · filed 3 Mar 2026
At a glance
- Sector
- Healthcare
- Industry
- Surgical & Medical Instruments & Apparatus
Source: SEC filings. Information and analytics, not investment advice.